Ocugen Inc. closed 73.92% short of its 52-week high of $2.11, which the company reached on March 25th.

Ocugen has received approval from the DSMB to begin dosing the second cohort of patients in a trial of OCU200 for diabetic ...

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic ...

Ocugen Inc. closed 75.47% below its 52-week high of $2.11, which the company reached on March 25th.

Ocugen (OCGN) announced that the Data and Safety Monitoring Board for the OCU200 clinical trial recently convened and reviewed safety data ...

HOUSTON, TX AND DANBURY, CT / ACCESS Newswire / March 6, 2025 / Camber Energy, Inc. and Go Green Global Technologies Corp. are pleased to announce the signing of a Memorandum of Understanding (MOU) to ...

Full Year 2024 Results Key Financial Results Net loss: US$54.1m (loss narrowed by 14% from ...

Ocugen Inc (OCGN) outlines pivotal trial progress and financial strategies while navigating increased expenses and market ...

Ocugen, Inc. (OCGN) reported its Q4 2024 earnings, showing a narrower-than-expected net loss and outperforming revenue forecasts. The company’s EPS stood at -$0.05, surpassing the forecasted -$0.06.

Operator Good morning, and welcome to Ocugen's fourth quarter and full-year 2024 financial results and business update.

Good morning, and welcome to Ocugen's Fourth Quarter and Full Year 2024 Financial Results and Business Update. Please note that this call is being recorded at this time. All participants' lines ...

Ocugen’s biologic candidate moved into the clinic and patients are currently being dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME). OCU200 has the potential to change ...